Phathom Pharmaceuticals

Phathom Pharmaceuticals

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$7.46-$18.31
Market Cap
$605.1M
Shares Short
10M

Financials

See more
Revenue (12 Mos)
$239.6M
Revenue Growth (YoY)
88%
Gross Profit (12 Mos)
$198.7M
Diluted EPS
-$1.21

News

See more

Yahoo Finance • 2 months ago

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Phathom Pharmaceuticals, Inc. (PHAT)

Yahoo Finance • 2 months ago

Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4

Yahoo Finance • 3 months ago

Phathom Pharma Completes Enrollment In Phase 2 PHalcon-EoE-201 For Eosinophilic Esophagitis

Yahoo Finance • 5 months ago

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

About

CEO
Mr. Steven L. Basta M.B.A.
Address
100 Campus Drive, Florham Park, NJ, United States, 07932
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
371